ClinicalTrials.gg
RecruitingNCT05872269Updated Feb 7, 2024

A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

A Phase 4 interventional study of Saroglitazar in NAFLD, Obesity and Type 2 Diabetes, sponsored by Zydus Lifesciences Limited. Recruiting at 19 sites in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Zydus Lifesciences Limited · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,500
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Non-alcoholic Fatty Liver Disease with a site in India — 10 open to participants now, 13 under way, 6 of them phase 3. Non-alcoholic Fatty Liver Disease · India.

Planned enrollment
4th of 39
1,500 · median 144
Started
2023
with 9 others
Phase 4
3 of 44
2 open now
Primary completion
2025-01
later than 0 of 12 live
Registered
32nd of 44
by date

Among the 44 studies in Non-alcoholic Fatty Liver Disease with a site in India, this one is the 4th largest by planned enrollment of the 39 interventional ones that give a count, is one of 10 that started in 2023, is one of 3 in phase 4, reaches primary completion later than 0 of the 12 other live ones, and was the 32nd registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

10 of the 44 studies in Non-alcoholic Fatty Liver Disease with a site in India are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Non-alcoholic Fatty Liver Disease with a site in India, or all of them as a file.
02

Study summary

A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome).

Read the detailed description

The study is being planned to evaluate long term safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD).

Total 1500 male and female patients with NAFLD with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome).

03

Conditions studied

  • NAFLD
  • Obesity
  • Type 2 Diabetes
  • Dyslipidemias
  • Metabolic Syndrome

Keywords

  • Real World Evidence Study
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged ≥18 years
  2. Patients who have been prescribed Saroglitazar for NAFLD will be included in this Phase 4 study (patients who use Saroglitazar for the first time)
  3. Patients able to and willing to provide written and comply with the requirements of the study protocol

    .

  4. Patients with a prior documented diagnosis of NAFLD based on the AASLD criteria. NAFLD is defined either by previous histology or clinical imaging in individuals who consume little or no alcohol and do not have a cause for secondary hepatic steatosis or another cause of chronic liver disease. In addition, patients must have one of the following criteria to indicate ongoing NAFLD at screening:

    1. Liver stiffness through transient elastography, an LSM ≥8 kPa OR
    2. Serum ≥45 U/L

Exclusion criteria

Exclusion Criteria:

  1. Consumption of alcohol for at least 90 consecutive days in last one year: >2 units of alcohol per day (>14 units per week) for males and >1 unit of alcohol per day (>7 units per week) for females. Note: 1 unit = 360 mL of beer, or 120 mL of wine, or 30 mL of spirits/hard liquor
  2. History of other chronic liver disease (Viral or C, hepatitis, cholestatic and metabolic liver diseases) and haemochromatosis.
  3. Patient has known documented cirrhosis, either based on clinical criteria or liver histology or imaging.
  4. to Saroglitazar or any disease conditions affecting the ability to evaluate the effects of Saroglitazar.
  5. History or other evidences of severe illness or any other conditions that would make patient, in the opinion of the investigator, unsuitable for the study.
  6. Any previous history of ascites, hepatic encephalopathy, oesophageal varices or admission/emergency department visit for hepatic decompensation.
  7. Women of child bearing potential: inability or unwillingness to practice for the duration of the study.
  8. Pregnant or breast feeding females
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Saroglitazar 4 mg tablets

    Oral (once daily ) during 364 days/52 weeks of treatment period.

    Drug: Saroglitazar

Interventions

06

What researchers measure

Primary outcomes

  1. Change in liver stiffness

    liver stiffness measurement performed by transient elastography

    Time frame: Baseline to Week 52

  2. Frequency and severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change in TG, HDL-C, LDL-C and non HDL-C levels

    Time frame: Baseline to Week 24 and Week 52

  2. Change in serum ALT value

    Time frame: Baseline to Week 24 and Week 52

  3. Change in serum AST value

    Time frame: Baseline to Week 24 and Week 52

  4. Change in serum ALP value

    Time frame: Baseline to Week 24 and Week 52

  5. Change in body weight

    Time frame: Baseline to Week 24 and Week 52

  6. Change in BMI

    Time frame: Baseline to Week 24 and Week 52

07

Study locations

19 of 19 sites recruiting
  • Gastroplus Digestive Disease Centre
    Ahmedabad, India
    Recruiting
    • Dr. Ravindra Gaadhe · Contact
  • Mission GastroHospital
    Ahmedabad, India
    Recruiting
    • Dr Chirag Shah · Contact
  • Artemis Hospital
    Gurgaon, India
    Recruiting
    • Dr Pawan Raval · Contact
  • Medanta- TheMedicity
    Gurgaon, India
    Recruiting
    • Dr Neeraj Saraf · Contact
  • Malla ReddyNarayanaMultispecialtyHospital
    Hyderabad, India
    Recruiting
    • Dr P Kranthi Kumar · Contact
  • Osmania GeneralHospital
    Hyderabad, India
    Recruiting
    • Dr B Ramesh Kumar · Contact
  • Yashoda Hospitals
    Hyderabad, India
    Recruiting
    • Dr B Ravishankar · Contact
  • CARE CHL -Hospitals (Unit ofConvenient HospitalLtd.
    Indore, India
    Recruiting
    • Dr Sandeep Julka · Contact
  • S R Kalla MemorialGastro and GenralHospital
    Jaipur, India
    Recruiting
    • Dr Mukesh Kalla · Contact
  • AIIMS
    Khorda, India
    Recruiting
    • Dr Manas Kumar Panigrahi · Contact
  • Medanta Hospital
    Lucknow, India
    Recruiting
    • Dr Abhai Verma · Contact
  • Dayanand MedicalCollege & Hospital
    Ludhiāna, India
    Recruiting
    • Dr Omesh Goyal · Contact
  • Neurociti Hospital
    Ludhiāna, India
    Recruiting
    • Dr Nitin Shanker Behl · Contact
  • TNMC & BYL NairCh. Hospital
    Mumbai, India
    Recruiting
    • Dr Shubham Jain · Contact
  • Shree Siddhivinayak Maternity & Nursing Home
    Nashik, India
    Recruiting
    • Dr Soham Doshi · Contact
  • Sir GangaramHospital
    New Delhi, India
    Recruiting
    • Dr Naresh Bansal · Contact
  • Alchemist Hospital
    Panchkula, India
    Recruiting
    • Dr Daksh Khurana · Contact
  • Fortis Hospital
    Rupnagar, India
    Recruiting
    • Dr Kiran Pal Singh · Contact
  • BAPS Pramukh Swami Hospital
    Sūrat, India
    Recruiting
    • Dr. Parshottam Koradia · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jan 2025, 17 months after the start.

Of 44 phase 4 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2023
First posted
May 24, 2023
StartActual
Jul 20, 2023
Primary completionEst.
Jan 10, 2025
CompletionEst.
Jun 10, 2025
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05872269
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Jul 20, 2023
Primary completion
Jan 10, 2025 (estimated)
Completion
Jun 10, 2025 (estimated)
Last update
Feb 7, 2024

Study contacts

Dr Kevin Kansagra, MD
Contact
kevinkumarkansagra@zyduslife.com
02717-665555 ext. 451
Dr. Deven Parmar, MD,FCP
study chair · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion